H.C. Wainwright analyst Joseph Pantginis notes that Rexahn and investigators announced positive interim Phase 2a data from the ongoing study combining RX-3117 with Abraxane in front-line pancreatic cancer. The analyst believes the "bright light" is now shining on RX-3117/Abraxane combo, and should get brighter with subsequent updates. Overall, Pantginis believes that the shares current valuation represents a significant disconnect to the underlying opportunity for RX-3117 and RX-5902. He reiterates a Buy rating and $19.50 price target on the stock.